Journal of Thrombosis and Thrombolysis

Papers
(The H4-Index of Journal of Thrombosis and Thrombolysis is 17. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
Characteristics and comparisons of acute stroke in “recovered" to “active COVID-19 and “pre-pandemic” in Qatar database54
Trends in management and outcomes of pulmonary embolism with a multidisciplinary response team39
Systemic bevacizumab to facilitate anticoagulation in antiphospholipid syndrome and bleeding gastrointestinal angiodysplasia31
Limb ischemia due to spontaneous heparin-induced thrombocytopenia as the primary presentation of acute COVID-19 infection31
Management of bone marrow biopsy related bleeding risks: a retrospective observational study29
Association of the careggi collateral score with radiological outcomes after thrombectomy for stroke with an occlusion of the middle cerebral artery29
Contact system activation in disseminated intravascular coagulation: activities of prekallikrein and high-molecular-weight kininogen are significant risk factors25
Italian experience with rVIII-single chain: a survey of patients with haemophilia A and their physicians24
Direct oral anticoagulants for secondary stroke prevention in patients over 80 years of age: the role of geriatric functional status23
Variables associated with adequate INR reversal in warfarin treated patients receiving 4-factor prothrombin complex concentrate22
Extending INR testing intervals in warfarin patients at a multi-center anticoagulation clinic21
Predictors of symptomatic intracranial hemorrhage after endovascular treatment for acute large vessel occlusion: data from ANGEL-ACT registry21
Direct oral anticoagulant plasma levels in hospitalized COVID-19 patients treated with dexamethasone20
Management of potential drug-drug interactions with nirmatrelvir-ritonavir and oral anticoagulants: a case series18
Patterns of vascular access device use and thrombosis outcomes in patients with COVID-19: a pilot multi-site study of Michigan hospitals18
The pharmacokinetics of recombinant FXIII (catridecacog) from the MENTORTM2 trial to a real-world study: a head-to-head comparison17
Evaluation of outcomes with apixaban use for venous thromboembolism in hospitalized patients with end-stage renal disease receiving renal replacement therapy17
0.057000160217285